CAR T-Cell Therapy Market to Reach $13.6 Billion by 2031, New Research Targets Multiple Sclerosis

A recent MarketsandMarkets report projects the global CAR T‑cell therapy market to grow from $6.78 billion in 2026 to $13.56 billion by 2031, a compound annual growth rate of 14.9%. The expansion is driven by rising incidence of hematologic cancers such as leukemia, lymphoma and multiple myeloma, increased investment in cellular therapies, advances in manufacturing and gene‑editing technologies, and broader regulatory approvals across major health markets.

Separately, clinical investigators are evaluating CAR T‑cell therapy for multiple sclerosis (MS). Coverage by the BBC highlighted trials that aim to engineer patients’ T‑cells to eliminate pathogenic B‑cell populations driving the autoimmune attack on the central nervous system. Researchers are assessing safety endpoints, including cytokine release syndrome, and the potential for sustained remission compared with existing immunomodulatory drugs. The work represents a crossover of oncology‑derived immunotherapy into neuro‑inflammatory disease treatment.